ArticleJournal of family medicine and primary care2025
Role of platelet counts to spleen length ratio and platelet-albumin to spleen length ratio as non-invasive predictors of esophageal varices in chronic liver disease patients: A cross-sectional study in Eastern India.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of non-invasive serological and CT imaging parameters in assessing portal hypertensive gastropathy severity.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate and compare the diagnostic performance of the Platelet/Spleen Length (P/SL) ratio and a novel metric, the Platelet-Albumin/Spleen Length (P*Alb/SL) ratio, in predicting esophageal varices (EVs) among patients with chronic liver disease (CLD). Methods: A cross-sectional study was conducted over a period of 6 months, enrolling 121 newly diagnosed CLD patients without prior treatment for EV or CLD. Data collected, included demographic and clinical details, platelet count, serum albumin, and spleen length via ultrasonography. All patients underwent upper gastrointestinal endoscopy to assess EVs. The P/SL ratio was calculated by dividing platelet count (cells/μL) by spleen length (mm), and the Platelet-Albumin to Spleen Length (P*Alb/SL) ratio by dividing the product of platelet count and serum albumin (g/dL) by spleen length. Diagnostic performance was evaluated using receiver operating characteristic curve analysis and calculating sensitivity and specificity. Results: The P/SL ratio demonstrated an optimal cutoff of 856 with an area under the curve (AUC) of 0.924 (95% CI: 0.849-0.998), sensitivity of 92%, and specificity of 85.7%. The P*Alb/SL ratio had an optimal cutoff of 2194.5, achieving an AUC of 0.928 (95% CI: 0.864-0.992), sensitivity of 81%, and specificity of 95.2%. Both ratios exhibited strong diagnostic performance, with no significant difference between their AUCs ( Conclusion: The P/SL ratio proved to be an effective screening tool for EVs in CLD, with high sensitivity for early detection. The P*Alb/SL ratio showed similar or slightly superior diagnostic performance, with high specificity and fewer false positives, making it ideal for confirmation. Together, the sequential tandem use of P/SL followed by P*Alb/SL provides a practical strategy for risk stratification and patient management, while reducing reliance on the endoscopy and improving resource allocation, especially in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.